The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

KRTL Holding Group, Inc. (OTC: KRTL) is strategically expanding its presence in the heart of South America, where biodiversity flourishes and untapped ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Chubb and Amica are among the best home insurance companies in California. Many, or all, of the products featured on this page are from our advertising partners who compensate us when you take ...

Soligenix, Inc. (NASDAQ: SNGX) decreased in price early Tuesday, as the late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...

U.S. Rep. April McClain Delaney visited Kite, a biopharmaceutical company that uses cell therapy to treat cancer, in Urbana ...